US2008318313A1PendingUtilityA1
Method to Prevent Graft Rejection Using TGF-Beta to Induce T Suppressor Cells
Est. expiryApr 11, 2020(expired)· nominal 20-yr term from priority
Inventors:David A. Horwitz
A61K 39/001A61P 37/06A61K 2035/124C12N 2501/15A61K 2035/122A61K 40/4229A61K 40/418A61K 40/22A61K 40/11C12N 5/0636
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to compositions and methods useful for preventing graft rejection in a recipient following organ transplantation.
Claims
exact text as granted — not AI-modified1 . One or more suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor; b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC; and c) combining ex vivo said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce one or more recipient suppressor T cells.
2 . A population of suppressor T cells capable of decreasing graft rejection of a solid organ by a recipient made by the process comprising:
a) isolating peripheral blood mononuclear cells (PBMC) from a recipient and an organ donor; b) irradiating T cell-depleted mononuclear cells from said organ donor PBMC; c) combining ex vivo said recipient PBMC with said donor irradiated T cell-depleted mononuclear cells and a regulatory composition comprising TGF-β to induce a PBMC population comprising one or more recipient suppressor T cells; and d) wherein a recipient suppressor T cell population is produced by expanding said recipient suppressor T cells.
3 . The suppressor T cells according to claim 1 or 2 , wherein said regulatory composition further comprises cytokines selected from the group consisting of IL-2 and IL-15.
4 . The suppressor T cells according to claim 1 or 2 , wherein said PBMC from said recipient are enriched for CD4+ T cells.
5 . The suppressor T cells according to claim 4 , wherein said CD4+ cells are enriched for naive CD4+ T cells.
6 . The suppressor T cells according to claim 1 or 2 , wherein said PBMC from said recipient are enriched for CD8+ T cells.Join the waitlist — get patent alerts
Track US2008318313A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.